Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. These forward-looking statements are only predictions. Forward-looking statements made in this news release include, but are not limited to, statements regarding the purpose of the debt repurchase and the Company's path and timing to achieve Adjusted EBITDA run rate. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking Statements Learn more at follow us on Twitter and LinkedIn. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Aurora also has a controlling interest in Bevo Farms, North America's leading supplier of propagated agricultural plants. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives.
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.About AuroraĪurora is a global leader in the cannabis industry, serving both the medical and consumer markets.
Aurora's balance sheet remains amongst the strongest in the industry, with approximately $380 million of cash and cash equivalents (including approximately $52 million of restricted cash) inclusive of the transaction announced today, and the Company reiterates its expectation of achieving a positive Adjusted EBITDA run rate by December 31, 2022.
0 kommentar(er)
